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Abstract 
Background: The persistent appearance of viral strains that causes a resistant viral infection has led to continuous tri‑
als for the design and development of novel antiviral compounds. Benzoquinazoline compounds have been reported 
to exhibit an interesting antiviral activity. This work aims to study and evaluate the antiviral activity of a newly pre‑
pared 2‑thioxo‑benzo[g]quinazolin‑4(3H)‑one series against herpes simplex (HSV‑1 & 2) and coxsackievirus (CVB4).
Methods: The antiviral activity was performed using the MTT assay, in which Vero cells (obtained from the American 
Type Culture Collection, ATCC) were propagated in fresh Dulbecco’s Modified Eagle’s Medium (DMEM) and challenged 
with 104 doses of the virus. Thereafter, the cultures were treated simultaneously with two‑fold serial dilutions of the 
tested compound and incubated at 37 °C for 48 h. Molecular docking studies were done on the CVB4 2A proteinase 
enzyme using Molegro Virtual Docker software.
Results: The cytotoxicity (CC50), effective concentration (EC50) and the selectivity index (SI) values were determined. 
Based on their EC50 values, a number of the investigated compounds demonstrated weak to moderate activity rela‑
tive to their parents. Accordingly, compounds 5–9, 11, 15–18, 21, 22, 24, 25, 27 and 28 were active against CVB4, 
and compounds 5 and 24 were active against HSV‑1 and 2 in comparison to ribavirin and acyclovir, which were used 
as reference drugs.
Conclusion: The obtained results gave us some useful insights about the characteristic requirements for future trials 
to build up and design more active and selective antiviral 2‑thioxo‑benzo[g]quinazolin‑4(3H)‑one agents.
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Background
Herpes simplex (HSV-1 & 2) and Coxsackie B4 (CVB4) 
viruses belong to the alphaherpesvirinae and picorna-
viridae families, respectively. In contrast to HSV-1 and 
2 which classified as enveloped double-stranded DNA 
viruses, CVB-4 is non-enveloped RNA viruses. They are 
common human pathogens and considered a significant 
worldwide health concern [1–3]. A relatively wide range 
of diseases, ranging from asymptomatic, mild infections 
to serious illnesses, are caused by these viruses [4, 5]. In 
addition, infections by CVB4 have also been known to 
cause aseptic meningitis, encephalitis, pleurodynia, myo-
carditis, and pericarditis [5].
Viral infectious diseases pose a major challenge for 
modern medicaments because the viruses have high 
mutation rates, which allow them to escape immune 
systems and become resistant to the traditional antiviral 
drugs [6–10]. Furthermore, although the antiviral drugs 
for diseases caused by several types of viruses such as 
herpes are available clinically, but the high prevalence 
of viral infections for which there are no specific treat-
ments or the continuous appearance of new resistant 
viral strains are serious problems. This make the task of 
the development of new novel antiviral agents is essential 
[10].
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Recently, we have reported the biological activity of 
some prepared triazoloquinazolines against herpes sim-
plex (HSV-1 & 2) and CVB4. However, a number of these 
prepared compounds were found to possess remarkable 
and significant antiviral activity [11–13]. Furthermore, 
synthetic chemistry has shown that benzoquinazoline 
is a valuable precursor for elaborating many structur-
ally diverse bioactive molecules, particularly as influenza 
H5N1 and H1N1 antiviral agents [14–17]. In addition, 
some 2-aminobenzo[de]-isoquinoline-1,3-diones have 
been reported as antiherpetic agents [11].
In view of these evidences and an extension of our 
ongoing research on benzoquinazolines chemistry, we 
herein report the antiviral evaluation of a new series 
of 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives 
against HSV-1, HSV-2 and CVB4 viruses.
Results and discussion
We previously reported our findings regarding the anti-
viral activity of isoquinazoline and triazoloquinazoline 
derivatives. The results suggested that quinazolines can 
be good platform for designing a new antiviral agent 
[11–13]. Here, we are reporting the results of an anti-
viral investigation for a new series of 2-thioxo-benzo[g]
quinazolines 1–28 (Table  1 and Scheme  1) [18]. The 
evaluation of the synthesized compounds 1–28 against 
HSV-1, HSV-2 and CVB4 was assessed in  vitro using 
an MTT assay. Their cytotoxic effects were also evalu-
ated. Results obtained from this screening showed that 
most of the compounds demonstrated antiviral activ-
ity, which ranged from weak through moderate to high 
effects, based on EC50 and SI values relative to their par-
ent and reference drugs (Table  2). In accordance to the 
statistical analyses and in terms of SI as a marker for 
antiviral activity, all tested molecules have been classified 
into three groups: inactive- (SI < 2), active- (2 ≤ SI < 10) 
and very active-types (SI ≥  10) [19]. Accordingly, com-
pounds 5–9, 11, 15–18, 21, 22, 24, 25, 27 and 28 were 
active against CVB4. On the other hand, compound 5 
has shown activity against HSV 1 and 2, while 24 was 
found to be active against HSV 1. It may be noticed that 
the tested molecules 5 and 9 showed significant levels 
of high activity against CVB4, with SI values of 6.27 and 
5.77, whereas 15, 21 and 24 were less active (3.60, 3.73 
and 3.85, respectively) with regard to ribavirin (16.38). 
However, 6, 7, 8, 11, 16, 17, 18, 22, 25, 27 and 28 exhib-
ited moderate activity against CVB4, with SI values in the 
range of 2.05‒3.31. Moreover, compound 5 demonstrated 
good activity against HSV-1 and HSV-2 (SI =  4.28 and 
5.18, respectively) and 24 was active against HSV-1 
(SI = 2.61) in relation to ribavirin (41.93 and 24.69).  
In outlining the results in Table 2 and Fig. 1, it should 
be clarified that modifications on the lead structures 
1–3 afforded new structural features (5–28) with a wide 
range of effects against the HSV and CVB4 viruses. For 
instance, S-alkylated products 7–28 exhibited significant 
activity against Coxsackie B4. In particular, compounds 
7–9, 11, 15–18, 21, 22, 24, 25, 27 and 28 were more 
active than their parents 1–3. Moreover, variations in 
the type of the N-alkyl and S-alkyl (heteroalkyl) groups 
resulted in variations of the activity, in which compound 
9 represented against CVB4 as the most active among 
the S-alkylated compounds (SI  =  5.57). Compounds 
15, 21, 24 and 28 showed a pronounced activity against 
CVB4 (SI  =  3.60, 3.73, 3.85 and 3.31, respectively). In 
regard to anti-herpes activity, compound 1 was inactive, 
but its S-alkylated products 7–15 exhibited slight activ-
ity. Similarly, the parents 2 and 3 appeared less active 
than their chemically transformed products 16–21 and 
22–28, respectively. However, hydrazino products 5 and 
6 offered more advantages in terms of activity against 
HSV and CVB4 viruses. Depending on the values of the 
SI-parameter, 5 gave rise to the greatest activity against 
HSV-1 (4.28), followed by HSV-2 (5.18) and CVB4 (6.27). 
Moreover, the presence of the butyl group at the “R” 
position provided a significant effect against CVB4 and 
HSV viruses. This effect can be seen in both S-alkylated 
and hydrazino derivatives. However, the “R1” position 
requires a hydrophobic moiety to provide a selective 
antiviral activity against CVB4, as in compound 9. On 
the other hand, compound 5 exhibited a non-specific 
antiviral activity against CVB4 and HSV viruses. This 
effect also can be seen with compound 24 that has a 
3-cyanobenzyl moiety at “R1” position but with a phenyl 
group instead of butyl at “R” position.
To investigate the effect of the different variation of 
the original skeletons, a molecular docking experiment 
Table 1 Synthesized 2-thioxo-benzo[g]quinazolines (7–28)
CPs R R1 CPs R R1
7 Butyl Ethyl 18 Allyl 3‑methoxybenzyl
8 Butyl Allyl 19 Allyl 4‑chlorobenzyl
9 Butyl Benzyl 20 Allyl 2‑morpholinoethyl
10 Butyl 3‑methoxybenzyl 21 Allyl 3‑(phthalimido‑2‑yl)
propyl
11 Butyl 4‑chlorobenzyl 22 Phenyl Ethyl
12 Butyl 4‑cyanobenzyl 23 Phenyl Allyl
13 Butyl 2‑piperidinoethyl 24 Phenyl 3‑cyanobenzyl




16 Allyl Ethyl 27 Phenyl 2‑morpholinoethyl
17 Allyl Allyl 28 Phenyl 3‑(phthalimido‑2‑yl)
propyl



















1 (R= butyl) 
2 (R= allyl) 
3 (R= phenyl) 
4 (R=cyclohexyl)
5 (R=butyl) 
6 (R= allyl)7-28 (R=butyl, allyl, phenyl)
Scheme 1 Synthetic route for 2‑thioxo‑benzo[g]quinazolines (1–28)
Table 2 Antiviral activity against HSVand CVB4 of compounds (1–28) in terms of CC50, EC50 (μg/mL) and SI
Cells treated with DMSO (0.1 %) were used as a negative control, and its reading was subtracted from the readings of tested compounds. Statistics were calculated 
using one‑way ANOVA
Cpd Nr. CC50 HSV-1 HSV-2 CVB4
EC50 SI EC50 SI EC50 SI
1 115.9 Inactive Inactive Inactive Inactive 272.4 0.43
2 173.1 247.5 0.70 213.8 0.81 149.2 1.16
3 376.5 428.1 0.88 361.6 1.04 342.4 1.10
4 824.7 706.4 1.17 649.2 1.27 478.9 1.72
5 3840 896.4 4.28 740.8 5.18 612.8 6.27
6 261.4 224.5 1.16 208.9 1.25 102.9 2.54
7 105.7 73.8 1.43 81.4 1.30 38.9 2.72
8 218.5 147.1 1.49 159.6 1.37 93.6 2.33
9 546.9 316.5 1.73 359.2 1.52 94.8 5.77
10 198.9 162.7 1.22 184.3 1.08 124.1 1.60
11 542.6 403.9 1.34 467.3 1.16 216.2 2.51
12 83.7 74.12 1.13 65.9 1.27 56.4 1.48
13 652.4 594.6 1.10 681.3 0.96 371.8 1.75
14 221.8 197.3 1.12 176.4 1.26 116.8 1.90
15 376.2 243.2 1.55 260.8 1.44 104.6 3.60
16 934.2 582.9 1.60 624.6 1.50 316.4 2.95
17 132.7 81.2 1.63 104.8 1.27 50.2 2.64
18 183.4 149.8 1.22 140.5 1.31 89.5 2.05
19 236.5 189.3 1.25 174.9 1.35 157.1 1.51
20 465.3 369.1 1.26 402.9 1.15 287.6 1.62
21 968.7 674.8 1.44 812.6 1.19 259.4 3.73
22 127.3 76.3 1.67 89.4 1.42 41.2 3.09
23 205.6 183.6 1.12 165.2 1.24 149.2 1.38
24 169.1 64.7 2.61 112.3 1.51 43.9 3.85
25 431.6 307.2 1.40 284.8 1.52 204.3 2.11
26 681.2 498.2 1.37 514.6 1.32 395.6 1.72
27 1034.8 >1000 Inactive >1000 Inactive 475.3 2.17
28 189.6 162.4 1.17 178.6 1.06 57.3 3.31
Acyclovir 648.2 2.3 281.83 1.06 144.04 – –
Ribavirin 486.4 11.6 41.93 11.3 24.69 29.7 16.38
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has been done with correlation to CVB4 2A proteinases. 
CVB4 2A proteinases perform essential roles involv-
ing viral polyprotein self-processing and shutting down 
of host-cell protein synthesis during viral replication. In 
addition, CVB4 2A proteinases also cleave heart muscle 
dystrophin, leading to cytoskeletal dysfunction and the 
symptoms of human-acquired dilated cardiomyopathy 
[20]. In silico docking experiments were performed for 
compounds 1–28 against the X-ray crystal structure of 
Coxsackievirus B4 2A proteinases (Protein Data Bank 
(PDB): 1Z8R) [20] using Molegro Virtual Docker soft-
ware. Docking results were then evaluated by the Mol-
Dock score function, and hydrogen bond interactions 
between tested compounds and the target receptor were 
used for comparison between the tested and reference 
compounds [21]. Ribavirin (reference drug) forms eleven 
hydrogen bonds with amino acid residues at the active 
site: Tyr 89, Asn 19, Glu 88, Gln 95, Asp 39 and Thr 125, 
and generated a MolDock score of –100.84 (Fig. 2).
Compounds 1–6 had MolDock scores ranging from 
−81.42 to −84.81  (Table  3). These scores increased 
from −84.82 to −126.89 in compounds 7–28, and 
reached the highest levels (−124.852, −124.156 and 
−126.899) in compounds 10, 18 and 24, respectively. 
However, compounds 10 and 18 have a 3-methoxy-
benzyl group at the “R1” position, but they are varied 
between each other with butyl group in compound 
10 and allyl group in compound 18 at the “R” posi-
tion. Even though, their MolDock scores were high 
but it did not enhance their antiviral activity. On the 
other hand, compound 24 that gave the highest Mol-
Dock score in this experiment has a phenyl group at 
“R” position and 3-cyanobenzyl group at “R1” position. 
Compound 24 made three hydrogen bonds with the 
Fig. 1 Antiviral and cytotoxicity evaluation of the synthesized compounds 1–28 compared to ribavirin and acyclovir. a Cytotoxicity effect (CC50). b 
Antiviral evaluation against CVB4 (EC50). c Antiviral evaluation against HSV‑2 (EC50). d Antiviral evaluation against HSV‑1 (EC50). All the values repre‑
sented in (μg/mL)
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amino acid residues (Tyr 89, Asn 19 and Glu 88) with 
CVB4 2A Proteinase enzyme (PDB: 1Z8R) active site 
(Fig.  3). Interestingly, the para position of “R1” sub-
stituted benzyl group, such as compound 12, did not 
enhance the MolDock score than the meta position as 
in compound 10 and 18. This supports the notion that 
a hydrophobic moiety at the “R” position is important 
for the protein binding and the wide range of antiviral 
activity against CVB4 and HSV. We propose that the 
phenyl group in compound 24 might participate in a 
non-polar staking interaction. Moreover, the quality of 
the docking process was attributed to the good over-
lapping of compound 24 with ribavirin in the active 
site (Fig. 4). Taking into account the preceding results, 
S-alkylated products 7–28 demonstrated good interac-
tion with CVB4 with regard to the parent compounds 
(1–3), along with 9, 21 and 24 that indicate good rela-
tion with the biological results in Table 3.  
Methods
Mammalian cell line
The source and methodology for preparation of the Vero 
cells were reported in details by Al-Salahi et collabora-
tors [11]. The GHSV-UL46, G and E2 viral strains were 
used for the assay of HSV-1, HSV-2 and CVB4 viruses, 
respectively.
Evaluation of the antiviral activity
Screening of the antiviral was performed using MTT 
assay. According to the literature [11, 22, 23], the Vero 
cells were cultured, then treated with two-fold serial dilu-
tions of the tested compounds, starting from 1000 μg/mL 
and diluting to about 2 μg/mL (1000, 500, 250, 125, 62.5, 
31.25, 15.63, 7.81, 3.91, 1.95 μg/mL). Six wells were used 
for each concentration of the tested compound and three 
independent experiments were assessed, each contain-
ing four replicates per treatment [24]. Untreated Vero cell 
control and infection controls were made in the absence 
of tested compounds. Acyclovir and ribavirin were used 
as positive controls in this assay [25].
After incubating for 48  h, the numbers of viable cells 
were determined by the MTT test. Briefly, the medium 
was removed from the 96-well plate and replaced with 
100 μL of fresh RPMI 1640 medium without phenol red, 
then 10 μL of the 12 mM MTT stock solution [5 mg of 
MTT in 1 mL of phosphate-buffered saline (PBS)] to each 
well, including the untreated controls. The 96-well plates 
were then incubated at 37  °C and 5  % CO2 for 4  h. An 
85 μL aliquot of the medium was removed from the wells, 
and 50 μL of dimethyl sulfoxide (DMSO) were added to 
each well, mixed thoroughly with the pipette, and incu-
bated at 37 °C for 10 min. Then, the optical density was 
measured at 590  nm with a microplate reader (Sunrise, 
Tecan U.S. Inc., USA) to determine the number of viable 
cells [11, 22, 26].
The viral inhibition rate was calculated as follows:
where ODtv, ODcv and ODcd indicate the absorbance 
of the tested compounds with virus-infected cells, the 
absorbance of the virus control and the absorbance of the 
Viral Inhibition Rate
= [(ODtv − ODcv)/(ODcd− ODcv)] × 100 %,
Fig. 2 Ribavirin shows hydrogen bonds interactions with CVB4 2A 
Proteinase enzyme (PDB: 1Z8R) active site
Fig. 3 Compound 24 shows hydrogen bonds interactions with CVB4 
2A Proteinase enzyme (PDB: 1Z8R) active site
Fig. 4 Compound 24 superimposed with Ribavirin in CV B4 2A 
Proteinase enzyme (PDB: 1Z8R) active site
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cell control, respectively. The EC50 was estimated with 
respect to the virus control from the graphic plots, using 
STATA modelling software and (SI) calculated from the 
ratio of CC50 to EC50 [11, 26].
Cytotoxicity evaluation using viability assay
The procedure for seeding and incubation of Vero cells 
was explained in details in previous research [11, 23, 
27]. After the end of the incubation period, the number 
of viable cells was determined by the MTT test. Briefly, 
the medium was removed from the 96-well plate and 
replaced with 100 μL of fresh RPMI 1640 medium with-
out phenol red, then 10 µL of the 12  mM MTT stock 
solution (5  mg of MTT in 1  mL of PBS) to each well 
including the untreated controls. The 96-well plates were 
then incubated at 37  °C and 5 % CO2 for 4 h. An 85 μL 
aliquot of the medium was removed from the wells, 
and 50  μL of DMSO were added to each well, mixed 
thoroughly with the pipette, and incubated at 37  °C 
for 10  min. Then, the optical density was measured at 
590 nm with the microplate reader (Sunrise, Tecan U.S. 
Inc., USA) to determine the number of viable cells. With-
out added stain, all obtained findings were corrected for 
background absorbance detected in wells. In the absence 
of the tested compounds, treated samples were compared 
with the cell controls. All experiments were carried out 
in triplicate. The cytotoxicity of each tested compound 
was calculated [24, 25, 27, 28].
The percentage cell viability, calculated using Microsoft 
Excel®, is as follows: 
where Abs equals the absorbance at 590  nm. The 
STATA statistical analysis package was used for the dose 
response curve, which was used to calculate CC50.
Data analysis
Statistical analysis was done using a one-way ANOVA 
test [29]. All experiments and data analysis of the anti-
viral and cytotoxicity evaluations were carried out in 
RCMB, Al-Azhar University, Cairo, Egypt.
Molecular docking
The modelling studies were done by a PC with Intel© 
Core™ i7-3630 QM CPU (2.40  GHz, RAM 8  GB) oper-
ating under the Windows 7 Professional Operating Sys-
tem [11]. The modelling processes included several steps: 
first, download the 3D crystal structures of the Coxsacki-
evirus B4 2A proteinase enzyme with PDB code 1Z8R 
(Brookhaven Protein Data) [20], and then load this into 
the Molegro Virtual Docker (MVD 2013.6.0 [Win32]) 
program (fully functional, free trial version with 
time limiting license; Molegro Virtual Docker (MVD 
2013.6.0), Molegro Bioinformatics Solutions, Denmark, 
2013; Thomsen and Christensen, 2006). ChemBio3D 
Ultra 10 [30] was used to draw the 3D structures of dif-
ferent ligands. Ligands were further optimized using a 
free version of Marvinsketch 4.1.13 (Marvinsketch, ver-
sion 6.1.0, Chemaxon, Budapest, Hungary; http://www.
chemaxon.com, 2013) with MM force field, and saved in 
Tripos mol2 file format. MolDock score functions were 
used with a 0.3 A° grid resolution. Prior to the calcula-
tion of the MolDock scores of the tested compounds, the 
MVD software was benchmarked docking ribavirin [11].
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